Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

Callander, Jenny, Robson, Y., Ingram, John R. ORCID: https://orcid.org/0000-0002-5257-1142 and Piguet, Vincent 2018. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. British Journal of Dermatology 179 (6) , pp. 1248-1255. 10.1111/bjd.14726

Full text not available from this repository.

Abstract

Clinically amyopathic dermatomyositis (CADM) affects a subset of 5–20% of patients with dermatomyositis and is defined as the presence of cutaneous features of dermatomyositis without clinical muscle weakness for ≥ 6 months. There is no consensus on first‐line treatment for CADM and whether treatment should differ from treatment of classic dermatomyositis with muscle weakness. We carried out a systematic review of published literature about treatment of adult patients with CADM, via the Embase, Medline, CINAHL and ClinicalTrials.gov databases on 17 February 2015. The aim was to establish which treatments have been used for adult‐onset CADM and what evidence is available regarding the efficacy of these treatments including topical treatments, dapsone, antimalarials, intravenous immunoglobulin (IVIG), nonsteroidal oral immunosuppressants and biological therapies. Eighteen cases series and 42 case reports were found. These provided data on 153 adult patients who met the inclusion criteria. No randomized controlled trials or robust observational studies were found. The majority of patients (60%) had tried more than one treatment due to side‐effects or lack of efficacy. Antimalarial agents were the most commonly used treatment type. In the majority of patients (55%), antimalarial treatments were discontinued due to lack of improvement or inability to wean concomitant steroids. IVIG was the treatment that led to improvement or remission in the greatest proportion of patients. Further robust, high‐quality studies are needed to assess treatment efficacy in CADM without bias.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Wiley-Blackwell
ISSN: 0007-0963
Date of Acceptance: 11 May 2016
Last Modified: 19 Feb 2023 15:21
URI: https://orca.cardiff.ac.uk/id/eprint/100503

Citation Data

Cited 21 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item